
Quarterly report 2023-Q3
added 11-09-2023
Applied Molecular Transport Market Cap 2011-2026 | AMTI
As of January 14, 2026 Applied Molecular Transport has a market cap of $ 10.1 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Applied Molecular Transport
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.1 M | 247 M | 1.12 B | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.12 B | 22.1 M | 462 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.37 | -8.67 % | $ 350 M | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
Adagene
ADAG
|
87.8 M | $ 1.65 | 6.11 % | $ 92.9 M | ||
|
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.43 | -2.69 % | $ 8.25 B | ||
|
Biogen
BIIB
|
19.3 B | $ 177.93 | -4.15 % | $ 25.9 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
6.25 B | $ 65.89 | -0.06 % | $ 8.81 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
AstraZeneca PLC
AZN
|
81.2 B | $ 94.4 | 0.82 % | $ 96.9 B | ||
|
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
7.37 B | $ 214.55 | 2.77 % | $ 5 B | ||
|
Codiak BioSciences
CDAK
|
240 M | - | -55.98 % | $ 2.15 M | ||
|
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | ||
|
Bristol-Myers Squibb Company
BMY
|
114 B | $ 55.84 | 0.13 % | $ 113 B | ||
|
Cerevel Therapeutics Holdings
CERE
|
6.68 B | - | - | $ 7.29 B | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
Caladrius Biosciences
CLBS
|
3.58 M | - | -16.75 % | $ 25.8 M | ||
|
BioLineRx Ltd.
BLRX
|
1.35 B | $ 2.86 | - | $ 908 M | ||
|
Clearside Biomedical
CLSD
|
101 M | - | - | $ 25.3 M | ||
|
Chimerix
CMRX
|
104 M | - | - | $ 756 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M | ||
|
BioNTech SE
BNTX
|
62.9 B | $ 106.88 | 4.6 % | $ 27.2 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 4.18 | -1.65 % | $ 9.1 B | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
Catalyst Biosciences
CBIO
|
33.6 M | $ 11.09 | 1.0 % | $ 730 M | ||
|
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | ||
|
Coherus BioSciences
CHRS
|
209 M | $ 1.69 | 2.12 % | $ 159 M | ||
|
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.31 B | $ 28.99 | -1.39 % | $ 1.4 B | ||
|
Celldex Therapeutics
CLDX
|
1.31 M | $ 25.71 | 0.16 % | $ 1.66 M | ||
|
CTI BioPharma Corp.
CTIC
|
551 M | - | - | $ 1.2 B | ||
|
Cellectis S.A.
CLLS
|
203 M | $ 4.24 | -0.47 % | $ 116 M | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
2.09 B | $ 9.57 | -0.78 % | $ 1.55 B |